Filtered By:
Drug: Tamoxifen
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 2054 results found since Jan 2013.
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
CONCLUSION: Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer.PMID:37079878 | DOI:10.1200/JCO.22.00577
Source: Clinical Genitourinary Cancer - April 20, 2023 Category: Cancer & Oncology Authors: Takuji Iwase Shigehira Saji Kotaro Iijima Kenji Higaki Shoichiro Ohtani Yasuyuki Sato Yasuo Hozumi Yoshie Hasegawa Yasuhiro Yanagita Hiroyuki Takei Maki Tanaka Hideji Masuoka Masahiko Tanabe Chiyomi Egawa Yoshifumi Komoike Toshitaka Nakamura Hiroshi Ohtsu Source Type: research
A functional genetic screen for metabolic proteins unveils GART and the de novo purine biosynthetic pathway as novel targets for the treatment of luminal A ER α expressing primary and metastatic invasive ductal carcinoma
In conclusion, GART inhibition by LMX or other inhibitors of the de novo purine biosynthetic pathway could be a novel effective strategy for the treatment of primary and metastatic BCs.
Source: Frontiers in Endocrinology - April 18, 2023 Category: Endocrinology Source Type: research
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
Curr Treat Options Oncol. 2023 Apr 15. doi: 10.1007/s11864-023-01082-3. Online ahead of print.ABSTRACTFor high-risk early-stage hormone-receptor-positive, HER2-negative breast cancer (HR + /HER2 - EBC), short- and long-term recurrence risks remain substantial despite local control with surgery and radiation and systemic treatment with chemotherapy and endocrine therapy (ET). Recent trials have provided new strategies for reducing recurrence. The monarchE trial demonstrated that adding 2 years of adjuvant abemaciclib to ET improves invasive disease-free survival (iDFS) and distant recurrence-free survival (DRFS). In the Oly...
Source: Cancer Control - April 15, 2023 Category: Cancer & Oncology Authors: Jamie O Brett Erica L Mayer Source Type: research
Cell-Autonomous Constitutive gp130 Signaling in T Cells Amplifies TH17 Cell Responses and Causes Severe Lung Inflammation
In conclusion, cell-autonomous gp130 signaling alters T cell differentiation. Although gp130 signaling is not sufficient for TH17 cell differentiation, it still promotes accumulation of activated T cells in the lung that cause tissue inflammation.PMID:37058116 | DOI:10.4049/jimmunol.2200461
Source: Journal of Immunology - April 14, 2023 Category: Allergy & Immunology Authors: Lisa Charlotte Heinig Emily Valentina Madelaine Huth Karsten Yan Neele Schumacher Mikolaj Nawrocki Niels Christian Lory Peter Bradtke Tabea Bertram Guido Rattay Joanna Schmid Samuel Huber Thorsten Wiech Dirk Schmidt-Arras Stefan Rose-John Hans-Willi Mittr Source Type: research
Effects of genetic polymorphisms of drug metabolizing enzymes and co-medications on tamoxifen metabolism in black South African women with breast cancer
In conclusion, CYP2D6 polymorphisms affected endoxifen concentration and the variants CYP2D6*17 and CYP2D6*29 significantly contributed to low exposure levels of endoxifen. This study also suggests a low risk of drug-drug interaction in breast cancer patients on tamoxifen.PMID:37042388 | DOI:10.1002/cpt.2904
Source: Clinical Breast Cancer - April 12, 2023 Category: Cancer & Oncology Authors: Shingirai M Chiwambutsa Oluwatosin Ayeni Nyasha Kapungu Comfort Kanji Roslyn Thelingwani Wenlong Carl Chen Dikeledi H Mokone Daniel S O'Neil Alfred I Neugut Judith S Jacobson Paul Ruff Herbert Cubasch Maureen Joffe Collen Masimirembwa Source Type: research
A 49-Year-Old Woman With Exertional Dyspnea and Dizziness
Chest. 2023 Apr;163(4):e157-e162. doi: 10.1016/j.chest.2022.10.040.ABSTRACTA 49-year-old woman with a history of right breast cancer status post radiation therapy presented to our ED with increasing chest pain, exertional dyspnea, fatigue, and dizziness for several weeks. She denied syncope or near-syncope, and she had no personal or family history of cardiac disease. Her outpatient medications included tamoxifen and venlafaxine.PMID:37031986 | DOI:10.1016/j.chest.2022.10.040
Source: Chest - April 9, 2023 Category: Respiratory Medicine Authors: Nina Liu Ahmadreza Ghasemiesfe Fatma Sen Edris Aman Ezra A Amsterdam Sandhya Venugopal Source Type: research
